BrightGene Bio-Medical Technology (SHA:688166) secured the approval of China's medical products administrator for the listing of dopamine hydrochloride as a chemical active pharmaceutical ingredient.
dopamine hydrochloride is suitable for treating shock syndromes caused by myocardial infarction, trauma, endotoxin sepsis, heart surgery, kidney failure or congestive heart failure, according to a Tuesday filing with the Shanghai bourse.
Shares of the pharmaceutical company closed 2% lower Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.